New drug combo aims to beat tough childhood cancer
NCT ID NCT06023641
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding liposomal irinotecan to standard chemotherapy can help children with intermediate- or high-risk rhabdomyosarcoma live longer without their cancer returning. Participants receive different drug combinations based on their risk level, along with radiation therapy if needed. The goal is to find safer, more effective treatments for this rare childhood cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- liposomal irinotecan, vincristine, dactinomycin, temozolomide, cyclophosphamide, vinorelbine
- What this could lead to
- If successful, this could improve survival rates for children with aggressive rhabdomyosarcoma by using targeted chemotherapy combinations.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply broadly. Chemotherapy side effects can be severe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cook Children's Medical Center
NOT_YET_RECRUITINGFort Worth, Texas, 76104-2796, United States
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Email: •••••@•••••
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle childhood sarcoma?
- Can AI read tumor slides to outsmart childhood cancer?
- Ultrasound, CT, and MRI put to the test for identifying childhood neck lumps
- Combination drug approach aims to tackle tough childhood cancer
- Targeted radiation zaps childhood brain tumors in early trial
- Dietary change explored as cancer support strategy